Equities.com client Beleave experienced a 30-Day average trading volume increase of 2500% over six months working with Equities.com Investor Targeting Solutions

1. Marke&ng
to
Investors
Finding
the
Right
Investors
in
the
Public
Markets
Equi%es.com
Case
Study
Series
Case
Study
4.0
Beleave,
Inc
May,
2017

2. Beleave,
Inc
(OTCQX:BLEVF
BE:CNX)
Beleave,
Inc
engaged
Equi&es
in
April
of
2016
to
solidify
their
digital
footprint.
The
goals
were
to
use
Equi&es’
research-­‐driven
content
and
distribu&on
network
to
target,
track,
and
deliver
relevant
interested
investors
to
the
Beleave
story.
As
Beleave
released
public
news,
the
Equi&es
content
team
generated
fresh
editorial
pieces
highligh&ng
the
most
relevant
data
points
with
support
from
Beleave’s
execu&ves
using
interviews
with
client
services
and
our
writers.
We
posi&oned
Beleave
on
the
Equi&es’
homepage
and
throughout
the
site
highligh&ng
their
story
on
their
&cker
page.
The
company’s
profile
became
the
center
of
a[en&on.
We
delivered
Beleave
interested
investors
and
liquidity.
While
the
Equi&es’
value
proposi&on
focuses
on
delivering
qualified
relevant
investors
to
a
company’s
story,
we
do
measure
success
based
on
increased
liquidity.
Of
course,
liquidity
is
a
result
of
numerous
variables
in
the
market,
but
according
to
our
research
we
have
seen
similar
results
across
our
clients.
We
also
no&ce
a
hedge,
derived
from
the
expansion
of
the
shareholder
base,
that
creates
more
liquidity
and
therefore
lessens
vola&lity
in
these
thinly-­‐traded
markets.
Case
Study
.04
2
Did
you
know?
Equi%es.com
Total
Client
Market
Cap
rose
from
$1B
to
$1.3B
in
Q1
2017.
5/19/17
2017
Copyright
Equi&es.com
Inc.

3. Beleave,
Inc
Cri.cal
Success
Factors:
Equi&es
knows
the
audience,
how
to
write
to
them,
when
to
place
content,
where
to
place
content,
and
how
to
distribute
accordingly.
Equi&es
maintains
ongoing
engagement
with
the
client,
but
stresses
control
over
product.
Equi&es.com
created
a
plan
with
Beleave
and
developed
a
consistently
clear
model,
and
delivered
on
their
investor
targe&ng
goals.
We
focused
on
the
company’s
news
flow,
and
followed
it
as
it
unfolded
organically.
We
wrote
the
facts,
as
provided
by
Beleave
via
public
press
releases,
and
delivered
a
series
of
ar&cles
that
were
leveraged
to
find
poten&al
investors
plus
influencers.
All
content
is
compliant
with
US
disclosure
rules
and
all
ar&cles
are
archived
on
Equi&es.com,
providing
an
addi&onal
layer
of
risk
mi&ga&on
under
general
solicita&on
rules.
In
addi&on
to
being
featured
on
our
plaaorm
and
Equi&es.com
newsle[er,
we
strategically
targeted
relevant
media
outlets
and
investors
using
na&ve
adver&sing,
and
distributed
content
on
those
plaaorms.
Once
clicked,
the
user
was
sent
to
the
Equi&es
page
and/or
Beleave‘s
investor
rela&ons
page.
At
the
same
&me,
once
clicked,
current
and
future
content
followed
the
user.
About
The
Na&ve
Adver&sing
Results
Results
from
the
campaigns
are
delivered
monthly
in
a
report
so
that
clients
can
observe
which
stories
are
resona%ng
and
the
correla%on
between
news,
volume
and
price.
3
5/19/17
2017
Copyright
Equi&es.com
Inc.

4. Problem
Being
Solved
Na&ve
Adver&sing
Distribu&on
ARTICLE BREAKDOWN:
4
5/19/17
2017
Copyright
Equi&es.com
Inc.
Release Date
Release Date
Article Title
Article Title
#Reads
#Reads TOS*
TOS* Clicks**
PRESS RELEASE BREAKDOWN:
*Time on Site
**Clicks via Native
Advertising
*Time on Site
**Includes GNW Distribution
5855 Green Valley Circle Suite 101 Culver City, CA 90230 // 310.822.5500 // clients@equities.com
4/26/2017 Beleave (BE: CNX) Beginning Clinical Research to Investigate Cannabinoids for Pain
Management
98 2:22
3/10/2017 Beleave Inc. (CSE: BE) Announces Pre-License Inspection Date for March 15th 459 2:50
3/6/2017 Beleave (CSE: BE) and Ryerson University Continue Research and Development of Indus-
trial Processes
32 2:39
2/8/2017 Beleave (CSE: BE) and Ryerson University Collaborator Begin Patent Work by Expanding
on Recent Genetic Results
94 2:01
1/12/2016 Beleave (BE:CNX): Completes Facility Build Out and Upgrades in Advance of Expansion 214 3:58
12/14/2016 Beleave and Ryerson Develop Unique Approach for Cannabinoid Extraction and Recov-
ery
95 2:02
10/19/2016 Beleave Announces Adoption of Advance Notice By-Law 44 3:08
9/26/2016 Beleave Provides Business Update 204 3:09
9/22/2016 Beleave Closes Non-Brokered Private Placement for Gross Proceeds of $1,405,000 44 1:33
7/6/2016 Beleave Announces Debt Settlement for Common Shares and Issuance of Options 40 1:35
6/16/2016 Beleave Appoints Retired Lieutenant Colonel Dana Gidlow as Head of Veteran Affairs
and Community Outreach**
854 1:06
6/15/2016 Beleave Announces the Addition of Former Drug Prosecutor Chris Murphy to the Team** 745 2:44
6/9/2016 Beleave Announces Closing of Second Tranche of Private Placement 30 0:35
5/3/2016 Beleave Strengthens Advisory Board With Addition of Andrew Steane** 610 1:16
4/18/2016 Beleave Signs Letter of Intent With gDial Inc. Regarding Proprietary Drug Dosing, Detec-
tion, and Usage-Tracking Technology
43 4:00
4/13/2016 Beleave Completes Private Placement and Debt Settlement 45 2:03
2/10/2017 In Perfect Position: Beleave Inc. (CNSX: BE) is Well Poised for the Future of
Cannabis
2,272 3:30 N/A
2/2/2017 Beleave Inc. (CNSX: BE): Not All Marijuana Plays are Created Equal 2,019 1:51 N/A
8/28/2016 What does the New ACMPR mean for Canadian Marihuana Producers 1,603 5:24 N/A
6/27/2016 Beleave Gears Up for Canada’s Road to Marijuana Legalization with Key Ap-
pointments
4,235 3:03 1,299
5/3/2016 Beleave (BE) Strengthens Advisory Board With Addition of Andrew Steane 29 1:30 N/A
4/18/2016 Beleave (BE:CNX) Signs LOI with gDial Inc Regarding Proprietary Drug Dos-
ing, Detection, and Usage-Tracking Technology
177 1:40 N/A
4/13/2016 Beleave Inc. (BE:CNX) Canada’s Undiscovered Cannabis Biotech Gem 9,725 3:53 3,481

5. Volume
and
Traffic
Results
and
Analysis
This
analysis
starts
from
July
2016
and
con&nues
un&l
May
2017.
In
July
2016,
Beleave,
Inc
had
a
market
cap
of
about
$13,088,053
USD,
a
price
of
$.45,
and
a
30
day
average
volume
of
9,300
shares
per
day.
Beleave
started
leveraging
Equi&es
in
April
2016
when
they
signed
on
for
the
Extended
Visibility
Package.
One
of
the
key
KPIs
is
number
of
reads,
and
longer
&me-­‐-­‐-­‐on-­‐-­‐-­‐site
(TOS)
infers
that
investors
are
more
engaged
in
content.
As
a
result,
TOS
is
a
more
potent
measurement
for
engagment.
Powered
by
the
Equi&es.com
brand,
investors
spent
an
average
&me
of
site
at
2:28
minutes,
a
significant
increase
vs.
the
compe&&on.
Because
Beleave
u&lized
Equi&es
to
deliver
their
story,
the
company
saw
an
increase
in
price
reflected
through
volume
and
increased
shareholder
base.
They
received
the
benefits
of
reduced
vola&lity
companies
don’t
normally
see
in
the
micro-­‐-­‐-­‐cap
markets.
Equi&es’
credibility
a[racts
investors,
and
it’s
our
philosophy
in
consistency
that
steadies
the
increases
over
&me.
In
other
words,
liquidity
begets
liquidity,
and
vola&lity
is
reduced
due
to
the
increase
in
“buy
and
hold”
shareholders.
In
Beleave’s
case,
we
saw
a
combina&on
of
solid
management
on
their
part,
and
the
ability
to
expose
their
story
and
leverage
their
public
securi&es
in
the
most
cost
effec&ve
way
possible.
0
0
0.5
1
1.5
2
2.5
3
With
a
star&ng
market
cap
of
$13,088,053
USD,
a
price
of
$.45,
and
a
30
day
average
volume
of
9,300
shares,
Beleave
receive
substan&al
benefits.
Laying
the
groundwork
in
April
2016,
Beleave’s
30
day
average
trading
volume
increased
2500%,
market
cap
increased
404%,
and
stock
price
increased
442%
in
10
months.
Volume
5
5/19/17
2017
Copyright
Equi&es.com
Inc.

6. Full
Coverage
Solu.on
Beleave
sought
to
build
awareness
and
drive
new
investors
to
their
company.
Equi&es.com
had
defined
their
goals
as
the
following:
Marke.ng
Goals:
1. Market
Awareness
2. Target
relevant
investors
3. Track
relevant
investors
using
Na&ve
Adver&sing
4. Deliver
be[er
qualified
investors
to
Beleave
About
Beleave
Beleave
is
a
biotech
company
focused
on
the
produc&on
of
medical
marijuana
in
Canada.
The
Company's
wholly-­‐-­‐-­‐owned
subsidiary
First
Access
Medical
Inc.
has
applied
for
a
license
to
cul&vate
and
sell
medical
marijuana
at
its
facility
pursuant
to
the
Marihuana
for
Medical
Purposes
Regula&ons
outlined
by
Health
Canada.
The
Company
is
ac&vely
working
towards
the
development
of
patents
through
research
with
large
Canadian
ins&tu&ons
and
the
research
and
development
of
smoke
harm
reduc&on
products.
Connect
at
www.beleave.com
Solu&on
Recap
Equi.es.com
Case
Study
.04
Authors:
Ma[hew
Paul
Business
Development
Western
Region
215-­‐694-­‐1540
ma[p@equi&es.com
Eric
Kaczmarowski
Client
Development
310-­‐822-­‐5500
Eric.Kacz@equi&es.com
Contact:
Sales@equi&es.com
Go
online
Equi&es.com
ATTENTION:
Equi.es.com
makes
no
claim
whatsoever
that
we
will
drive
volume,
stock
price,
or
any
other
market
direc.on.
In
the
interest
of
full
disclosure,
we
call
the
reader's
a[en&on
to
the
fact
that
Equi&es.com,
Inc.
is
compensated
by
the
companies
profiled
in
the
Spotlight
Companies
sec&on.
The
purpose
of
these
profiles
is
to
provide
awareness
of
these
companies
to
investors
in
the
micro,
small-­‐-­‐-­‐cap
and
growth
equity
community
and
should
not
in
any
way
be
considered
as
a
recommenda&on
to
buy,
sell
or
hold
these
securi&es.
Equi&es.com
is
not
a
registered
broker
dealer,
investment
advisor,
financial
analyst,
investment
banker
or
other
investment
professional.
We
are
a
publisher
of
original
and
third
party
news
and
informa&on.
All
profiles
are
based
on
informa&on
that
is
available
to
the
public.
The
informa&on
contained
herein
should
not
be
considered
to
be
complete
and
is
not
guaranteed
by
Equi&es.com
to
be
free
from
misstatement
or
errors.
The
views
expressed
are
our
own
and
not
intended
to
be
the
basis
for
any
investment
decision.
Readers
are
reminded
to
do
their
own
due
diligence
when
researching
any
companies
men&oned
on
this
website.
Always
bear
in
mind
that
inves&ng
in
early-­‐-­‐-­‐stage
companies
is
risky
and
you
are
encouraged
to
only
invest
an
amount
that
you
can
afford
to
lose
completely
without
any
change
in
your
lifestyle.
Equi&es
has
been
compensated
with
cash,
common
shares
and/or
warrants
for
market
awareness
services
provided.
6
5/19/17
2017
Copyright
Equi&es.com
Inc.
• Posi&on
on
the
Equi&es.com
plaaorm:
Corporate
profile,
branding,
and
self-­‐
managing
social
investor
channel.
• Unlimited
news
coverage
on
Equi&es.com
homepage,
and
sent
daily
newsle[er
to
65,000
subscribers.
• Unlimited
sponsored
ar&cles-­‐-­‐-­‐stories
wri[en
on
an
ongoing
basis.
Ar&cles
are
based
on
material
press
releases.
• Four
in-­‐depth
C-­‐level
Spotlight
Ar&cles.
• 5800
clicks
via
Na&ve
Adver&sing.
Na&ve
Adver&sing
Network
is
an
addi&onal
45k
media
and
other
sites
collec&vely
making
up
billions
of
eyeballs
and
millions
of
clicks.
Sites
include
but
were
not
limited
to
Bloomberg,
Reuters,
Business
Insider,
The
Street,
Yahoo
Finance,
and
the
Wall
Street
Journal.